Innoviva, Inc. (INVA) News
Follow Innoviva, Inc. (INVA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Innoviva U.S. Net Product Sales Rose 45% to $43.3M in Q3
Innoviva said it remains on track to achieve 2026 guidance of at least $150 million in U.S. net product sales.
EQUITY | Nov 04, 2026, 09:34 PM UTC
M
Innoviva Reports Q3 Pretax Loss
Innoviva reported a Q3 net loss.
EQUITY | Nov 04, 2026, 09:12 PM UTC
M
Innoviva Reports Third-Quarter 2026 Financial Results
Innoviva reported its third-quarter 2026 financial results.
EQUITY | Nov 04, 2026, 09:06 PM UTC
M
Innoviva Q3'26 Earnings Preview: Revenue Estimate
Innoviva is scheduled to report Q3'26 results on November 11. Revenue and EPS estimates were provided; the release time is not specified.
EQUITY | Nov 04, 2026, 12:00 PM UTC
L
Innoviva Coverage Assumed by Oppenheimer at Outperform
Ratings actions from Benzinga: GMT) Innoviva Price Target Announced at $35.00/Share by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:24 PM UTC
L
INVA: Specialty therapeutics and innovative drug delivery drive growth, with resilient royalty streams funding expansion
Specialty therapeutics revenue exceeded $200 million, driven by XACDURO and GIAPREZA, with strong U.S. and ex-U.S. growth. Nortiva's LYNX platform targets once-monthly oral contraceptives, supported by the Gates Foundati
EQUITY | Sep 10, 2026, 01:40 PM UTC
L
INVA: Specialty therapeutics and innovative drug delivery drive growth, backed by stable royalties
Specialty therapeutics revenue exceeded $200 million, driven by strong growth in XACDURO and GIAPREZA, with global expansion through partnerships. Nortiva's LYNX platform targets once-monthly dosing, starting with a cont
EQUITY | Sep 10, 2026, 01:02 PM UTC
L
INVA - Innoviva to Participate in Upcoming Investor Conferences
INVA - Innoviva to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:08 PM UTC
L
Innoviva to participate in upcoming investor conferences
Innoviva says it will participate in upcoming investor conferences. The company describes its diversified biopharmaceutical focus, including a royalties portfolio and critical care and infectious disease platform.
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
INVA Therapies Named Finalists for Prix Galien USA Award
Innoviva Specialty Therapeutics' XACDURO, ZEVTERA, and NUZOLVENCE are finalists for the Prix Galien USA Best Pharmaceutical Product Award
EQUITY | Aug 11, 2026, 08:12 PM UTC
L
Innoviva Therapies Named Finalists
Innoviva's XACDURO, ZEVTERA, and NUZOLVENCE are finalists for the Prix Galien USA award
EQUITY | Aug 11, 2026, 08:05 PM UTC
L
INVA - Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
INVA - Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
EARNINGS | Aug 05, 2026, 08:17 PM UTC